On June 26, 2024, Changchun, China -- GenSci recently announced that its Jin Sai Xin? progesterone injection (II) (hereafter referred to as Jin Sai Xin), has received approval from the National Medical Products Administration (NMPA) of China. This approval is for the supplementary treatment of progesterone in assisted reproductive technology (ART), catering specifically to women who are unable to use or do not tolerate vaginal formulations.

As China's first aqueous solution progesterone injection, Jin Sai Xin is bioequivalent to its original drug counterparts. Research confirms that the subcutaneous injection method it utilizes is proven to minimize the risk of adverse reactions, significantly streamline the treatment process, and lower additional costs, while also enhancing patient compliance.

Assisted reproduction is a cornerstone of GenSci's robust Women's Health portfolio. The company's ongoing investment has yielded a successful launch of key products, such as the GnRH agonist Triptorelin, the GnRH antagonist Cetrorelix, and Follicle-Stimulating Hormone (FSH), each playing an indispensable role in fertility treatments.

Strategically leveraging assisted reproduction as its entry point, GenSci is committed to overseeing the full spectrum of women's health with vigor and foresight. Recognizing women's unique biological and reproductive attributes, GenSci delivers a wide array of health solutions, from assisted reproduction and menopausal support to the management of common gynecological conditions. This comprehensive approach aims to enhance women's well-being and ultimately reinforces GenSci's vision of becoming a global leader in Pediatric and Women's Health.